Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma

NCT03412773 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03412773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03412773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Lead sponsor
BeiGene
Phase
Phase 3
Overall status
Completed
Start date
December 18, 2017
Completion date
December 14, 2023
Enrollment
684 (actual)
Sites
122

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)